Needle-free Injection Offers Robust Immune Response

In a review article recently published in Vaccines Journal referenced over 25 studies and discussed multiple injection delivery methods, including PharmaJet's needle-free precision delivery systems.

This study found that needle-free delivery enhanced the clinical performance of DNA-based vaccines.

Currently, 250 vaccine programs are invested in DNA vaccines and therapeutics because of their potential benefits.

"We are enthused to see that pre-clinical results have translated into more effective clinical responses in human trials," said Chris Cappello, President and CEO of PharmaJet, in a press release on February 23, 2023. 

"We currently have eighty-three studies ongoing with novel pharmaceuticals focusing on nucleic acid technology and other new vaccine technology platforms."

"We believe that our precision delivery devices have the potential to increase the performance and therefore the probability of regulatory success of many of these candidate vaccines."

Several DNA candidate vaccines in combination with PharmaJet devices are in development, including for a COVID-19 bivalent booster, HIV, Zika, influenza, poxvirus, hantavirus, and dengue infections.